Abstract
Understanding the pathogenesis and pathophysiology of the hematologic malignancies now requires knowledge of their immunology. Many of these tumors appear to arise from the immune cells themselves (B or T cell tumors); most have associated disturbances in immune cell function. New immunodiagnostic methods may become potentially useful clinical tools for evaluating extent of disease, tumor cell kinetics, response to treatment, and prognosis.